FORTREA HOLDINGS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.03 USD | -7.76% |
|
-11.71% | -5.36% |
| Apr. 01 | Fortrea Holdings Inc. Announces the Resignation of Betty Larson as from the Board, and All Board Committees | CI |
| Mar. 22 | Baird Starts Fortrea Holdings With Neutral Rating, $43 Price Target | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 3.08B | Sales 2025 * | 3.16B | Capitalization | 2.95B |
|---|---|---|---|---|---|
| Net income 2024 * | -15M | Net income 2025 * | 83M | EV / Sales 2024 * | 1.29 x |
| Net Debt 2024 * | 1.02B | Net Debt 2025 * | 851M | EV / Sales 2025 * | 1.2 x |
| P/E ratio 2024 * |
-315
x | P/E ratio 2025 * |
34
x | Employees | 17,730 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fortrea Holdings Inc.
More recommendations
More press releases
| 1 day | -7.76% | ||
| 1 week | -11.71% | ||
| Current month | -9.73% | ||
| 1 month | -15.42% | ||
| 3 months | +3.87% | ||
| 6 months | +17.09% | ||
| Current year | -5.36% |
1 week
33.02
37.24
1 month
33.0239.49
Current year
29.4941.02
1 year
24.9341.02
3 years
24.9341.02
5 years
24.9341.02
10 years
24.9341.02
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 0 M€ | -.--% | - | |
| 0.00% | 0 M€ | +3.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 33.03 | -7.76% | 3,321,877 |
| 24-05-09 | 35.81 | +0.87% | 708,752 |
| 24-05-08 | 35.5 | -2.66% | 1,059,280 |
| 24-05-07 | 36.47 | +0.36% | 778,202 |
| 24-05-06 | 36.34 | -2.86% | 1,342,195 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Fortrea Holdings Inc. is a global contract research organization (CRO). The Company is providing clinical development, patient access solutions and consulting to the life sciences industry. The Company provides phase I through IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. The Company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment offers solutions to the market that include clinical pharmacology and comprehensive clinical development capabilities. Its Enabling Services segment provides patient access and technology solutions that can be deployed as a standalone offering or across its global solutions depending on the scope of its customersâ needs. The Company offers its customers with clinical trial solutions through three delivery models: Full Service, Functional Service Provider, and Hybrid.
Calendar
2024-05-12
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
33.03
USD
Average target price
39.79
USD
Spread / Average Target
+20.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.36% | 2.95B | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- FTRE Stock
